256 related articles for article (PubMed ID: 11786411)
21. Cell-cycle regulators, bcl-2 and NF-kappaB in Epstein-Barr virus-positive gastric carcinomas.
Chang MS; Lee HS; Jung EJ; Kim CW; Lee BL; Kim WH
Int J Oncol; 2005 Nov; 27(5):1265-72. PubMed ID: 16211221
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma.
Sinicrope FA; Hart J; Michelassi F; Lee JJ
Clin Cancer Res; 1995 Oct; 1(10):1103-10. PubMed ID: 9815900
[TBL] [Abstract][Full Text] [Related]
23. The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions.
Chiappetta G; Toti P; Cetta F; Giuliano A; Pentimalli F; Amendola I; Lazzi S; Monaco M; Mazzuchelli L; Tosi P; Santoro M; Fusco A
J Clin Endocrinol Metab; 2002 Jan; 87(1):364-9. PubMed ID: 11788677
[TBL] [Abstract][Full Text] [Related]
24. Altered expression of cell cycle regulatory proteins in gastrointestinal stromal tumors: markers with potential prognostic implications.
Sabah M; Cummins R; Leader M; Kay E
Hum Pathol; 2006 Jun; 37(6):648-55. PubMed ID: 16733203
[TBL] [Abstract][Full Text] [Related]
25. Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression.
Saltman B; Singh B; Hedvat CV; Wreesmann VB; Ghossein R
Surgery; 2006 Dec; 140(6):899-905; discussion 905-6. PubMed ID: 17188136
[TBL] [Abstract][Full Text] [Related]
26. Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma.
Weinberger PM; Adam BL; Gourin CG; Moretz WH; Bollag RJ; Wang BY; Liu Z; Lee JR; Terris DJ
Arch Otolaryngol Head Neck Surg; 2007 May; 133(5):503-10. PubMed ID: 17515507
[TBL] [Abstract][Full Text] [Related]
27. Biological differential diagnosis of follicular thyroid tumor and Hürthle cell tumor on the basis of telomere length and hTERT expression.
Sugishita Y; Kammori M; Yamada O; Yamazaki K; Ito K; Fukumori T; Yoshikawa K; Yamada T
Ann Surg Oncol; 2014 Jul; 21(7):2318-25. PubMed ID: 24562933
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma.
Phuoc NB; Ehara H; Gotoh T; Nakano M; Yokoi S; Deguchi T; Hirose Y
Urology; 2007 May; 69(5):843-8. PubMed ID: 17482919
[TBL] [Abstract][Full Text] [Related]
29. Approach the Invasive Potential with Hurthle Cell Tumors of Thyroid.
Ding L; Jiang Y; Yang W
Pathol Oncol Res; 2019 Apr; 25(2):697-701. PubMed ID: 30539520
[TBL] [Abstract][Full Text] [Related]
30. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
Ioachim E
Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
[TBL] [Abstract][Full Text] [Related]
31. Alterations of rb pathway components are frequent events in patients with oral epithelial dysplasia and predict clinical outcome in patients with squamous cell carcinoma.
Soni S; Kaur J; Kumar A; Chakravarti N; Mathur M; Bahadur S; Shukla NK; Deo SV; Ralhan R
Oncology; 2005; 68(4-6):314-25. PubMed ID: 16020958
[TBL] [Abstract][Full Text] [Related]
32. Frequent chromosomal DNA unbalance in thyroid oncocytic (Hürthle cell) neoplasms detected by comparative genomic hybridization.
Tallini G; Hsueh A; Liu S; Garcia-Rostan G; Speicher MR; Ward DC
Lab Invest; 1999 May; 79(5):547-55. PubMed ID: 10334566
[TBL] [Abstract][Full Text] [Related]
33. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.
Baretton GB; Klenk U; Diebold J; Schmeller N; Löhrs U
Br J Cancer; 1999 May; 80(3-4):546-55. PubMed ID: 10408865
[TBL] [Abstract][Full Text] [Related]
34. [Hurthle cell neoplasm: our experience].
Cristofaro MG; Vescio G; Fava MG; Aversa C; Amantea M; Giudice M
Ann Ital Chir; 2004; 75(6):663-8. PubMed ID: 15960361
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases.
Ghossein RA; Hiltzik DH; Carlson DL; Patel S; Shaha A; Shah JP; Tuttle RM; Singh B
Cancer; 2006 Apr; 106(8):1669-76. PubMed ID: 16534796
[TBL] [Abstract][Full Text] [Related]
36. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression.
Mhawech P; Greloz V; Oppikofer C; Szalay-Quinodoz I; Herrmann F
Cancer; 2004 Jun; 100(11):2367-75. PubMed ID: 15160340
[TBL] [Abstract][Full Text] [Related]
37. Immunoreactivity of p53, Ki-67, and Bcl-2 in oncocytic adenomas and carcinomas of the thyroid gland.
Müller-Höcker J
Hum Pathol; 1999 Aug; 30(8):926-33. PubMed ID: 10452505
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical analysis of expression of bcl-2 protein in papillary carcinomas and papillary microcarcinomas of the thyroid gland.
Mitselou A; Peschos D; Dallas P; Charalabopoulos K; Agnantis NJ; Vougiouklakis T
Exp Oncol; 2004 Dec; 26(4):282-6. PubMed ID: 15627060
[TBL] [Abstract][Full Text] [Related]
39. Anaplastic, sarcomatoid carcinoma of the thyroid originating from a Hürthle cell tumor.
Okoń K; Wierzchowski W; Jabłońska E; Wójcik P; Steczko A
Pol J Pathol; 2003; 54(4):277-81. PubMed ID: 14998298
[TBL] [Abstract][Full Text] [Related]
40. [Clinical experience in Hurthle cell tumors].
Francomano F; Napolitano L; Scipione P; Savini F; Bajocchi G; Angelucci D
G Chir; 1998; 19(11-12):449-52. PubMed ID: 9882947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
